ArticleJPGN reports2026
Return to baseline arsenic concentrations after 1 year on gluten-free diet in children with celiac disease: A prospective cohort study.
Article in JPGN reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Molybdenum-Closing the gap.JPGN reports · 2026Article
- Letter to Editor: Methodological constraints in assessing dietary and urinary molybdenum.JPGN reports · 2026Article
- Return to baseline arsenic concentrations after 1 year on gluten-free diet in children with celiac disease: A prospective cohort study.JPGN reports · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Objectives: Lifelong adherence to a gluten-free diet (GFD) is the primary treatment for celiac disease (CeD). Concerns have been raised about increased exposure to contaminants in a GFD because rice, which naturally bioaccumulates arsenic and other environmental contaminants, is commonly used as a substitute for gluten. In this study, we aimed to determine whether elevated urinary arsenic and other heavy metal concentrations, previously observed after 6 months on a GFD, persisted after 12 months on a GFD. Methods: Single-center prospective longitudinal cohort study of children (age 2-18 years) with biopsy-confirmed CeD who initiated a GFD between January and May 2022. The primary outcome was the change in urinary arsenic concentration between baseline diagnostic endoscopy and 12 months on a GFD. Results: Twenty-one of the 35 (60%) participants provided a follow-up sample. After 12 months on a GFD, total median urinary arsenic concentration returned to baseline (3.42 vs. 4.93 μg/L, Conclusions: Children with CeD may have increased arsenic exposure as they transition to a GFD, but concentrations return to baseline within 1 year. Future studies are needed to identify dietary contributors and guide strategies to limit excess arsenic exposure.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.